Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Finished Goods (2017 - 2025)

Neurocrine Biosciences filings provide 9 years of Finished Goods readings, the most recent being $13.6 million for Q1 2025.

  • On a quarterly basis, Finished Goods rose 81.33% to $13.6 million in Q1 2025 year-over-year; TTM through Mar 2025 was $13.6 million, a 81.33% increase, with the full-year FY2024 number at $12.8 million, up 4.07% from a year prior.
  • Finished Goods hit $13.6 million in Q1 2025 for Neurocrine Biosciences, up from $12.8 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $17.5 million in Q4 2022 to a low of $7.5 million in Q1 2024.
  • Median Finished Goods over the past 5 years was $12.5 million (2023), compared with a mean of $12.7 million.
  • Biggest five-year swings in Finished Goods: decreased 29.71% in 2023 and later surged 81.33% in 2025.
  • Neurocrine Biosciences' Finished Goods stood at $15.7 million in 2021, then grew by 11.46% to $17.5 million in 2022, then decreased by 29.71% to $12.3 million in 2023, then increased by 4.07% to $12.8 million in 2024, then grew by 6.25% to $13.6 million in 2025.
  • The last three reported values for Finished Goods were $13.6 million (Q1 2025), $12.8 million (Q4 2024), and $11.5 million (Q3 2024) per Business Quant data.